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Activation of Acid Sphingomyelinase and Its Inhibition by the
Nitric Oxide/Cyclic Guanosine 3,5-Monophosphate Pathway:
Key Events in Escherichia coli-Elicited Apoptosis of Dendritic
Cells1
Sestina Falcone,*†‡ Cristiana Perrotta,*§ Clara De Palma,*§ Addolorata Pisconti,*
Clara Sciorati,* Annalisa Capobianco,* Patrizia Rovere-Querini,* Angelo A. Manfredi,* and
Emilio Clementi2*†‡
Depletion of dendritic cells (DCs) via apoptosis contributes to sepsis-induced immune suppression. The mechanisms leading to DC
apoptosis during sepsis are not known. In this study we report that immature DCs undergo apoptosis when treated with high
numbers of Escherichia coli. This effect was mimicked by high concentrations of LPS. Apoptosis was accompanied by generation
of ceramide through activation of acid sphingomyelinase (A-SMase), was prevented by inhibitors of this enzyme, and was restored
by exogenous ceramide. Compared with immature DCs, mature DCs expressed significantly reduced levels of A-SMase, did not
generate ceramide in response to E. coli or LPS, and were insensitive to E. coli- and LPS-triggered apoptosis. However, sensitivity
to apoptosis was restored by addition of exogenous A-SMase or ceramide. Furthermore, inhibition of A-SMase activation and
ceramide generation was found to be the mechanism through which the immune-modulating messenger NO protects immature
DCs from the apoptogenic effects of E. coli and LPS. NO acted through formation of cGMP and stimulation of the cGMP-
dependent protein kinase. The relevance of A-SMase and its inhibition by NO/cGMP were confirmed in a mouse model of
LPS-induced sepsis. DC apoptosis was significantly higher in inducible NO synthase-deficient mice than in wild-type animals and
was significantly reduced by treatment ex vivo with NO, cGMP, or the A-SMase inhibitor imipramine. Thus, A-SMase plays a
central role in E. coli/LPS-induced DC apoptosis and its inhibition by NO, and it might be a target of new therapeutic approaches
to sepsis. The Journal of Immunology, 2004, 173: 4452–4463.
S epsis, a life-threatening disorder, is the most commoncause of death in intensive care units of the industrializedworld, and its incidence continues to increase (1). Despite
efforts in the identification of novel therapeutic strategies, no sig-
nificant improvement in the outcome of the disease has taken place
in the last decades (2). Recognition of patterns expressed by mi-
croorganisms can initiate a deregulated innate response in septic
patients, with exaggerated production of proinflammatory media-
tors, hypotension, inadequate tissue perfusion, and ensuing failure
of multiple organs (2). An additional major feature of septic pa-
tients, immune suppression, prevents clearing of invading agents,
promoting further activation of nonprotective, inflammatory re-
sponses, with frequent inability to eradicate primary infections and
propensity to secondary nosocomial infections (3–6). Various de-
fects in immunological functions, including depression of Th1 and
Th2 cytokines, loss of CD4 T and B cells, and monocyte deac-
tivation, have been reported (4–8). Recent studies, conducted in
both an animal model and tissues from affected patients, demon-
strated a profound depletion of dendritic cells (DCs),3 including
interdigitating and follicular cells, due to death via apoptosis (9,
10). DCs play fundamental roles in the coordination of the immune
responses against invading microorganisms, including sustaining
the growth and viability of activated T and B cells and polarization
of CD4 T cells toward a defined Th phenotype (11, 12). Deple-
tion of DCs might thus be relevant to the pathogenesis and main-
tenance of immune suppression during sepsis. The mechanisms by
which sepsis triggers DC apoptosis are at present largely unex-
plored. Elucidation of these mechanisms might ultimately be of
great help in defining novel therapeutic strategies to treat this
disorder.
Among sepsis-causing organisms, Gram-negative bacteria are
estimated to result in 20.000 death annually in the U.S. (13). LPS,
a potent inflammatory glycolipid residing in the outer membrane
of these bacteria, contributes to the pathogenesis of Gram-negative
septic shock (14). LPS exerts its effects through the activation of a
variety of messenger molecules, including transcription factors, G
proteins, protein kinases, and the sphingolipid ceramide (15–23).
Ceramide derives from sphingomyelin hydrolysis, conducted by
the neutral and/or the acid sphingomyelinases, or through de novo
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synthesis from sphinganine. Ceramide has been shown to be pro-
apoptotic in many cell types, contributing to the effects induced by
death receptor activation and environmental and chemotherapeutic
agents (24–26). A role for ceramide in the apoptogenic effect of
LPS has been demonstrated in endothelial cells (27); in addition, it
triggers apoptosis of DCs (28).
In this study we investigated the effect of the Gram-negative
bacterium, Escherichia coli, on the survival of DCs. We found that
high numbers of E. coli induced apoptosis of immature DCs in
vitro, and that this effect was mimicked by high concentrations of
LPS. Such responses required the activation of acid sphingomy-
elinase (A-SMase) and the ensuing ceramide generation. We also
found that A-SMase is a target for NO, a gaseous messenger that
plays important roles in inflammation partly through the regulation
of apoptosis in immune-competent cells (29–33). NO inhibited
A-SMase activation and ceramide generation in a pathway involv-
ing formation of cGMP and stimulation of the cGMP-dependent
protein kinase (G kinase). Inhibition of A-SMase by NO/cGMP
resulted in protection of immature DCs from apoptosis induced by
E. coli and LPS. Using an in vivo model of sepsis, we confirmed
the biological relevance of A-SMase activation and its regulation
by endogenous NO in determining the survival of DCs during
sepsis. Our findings reveal for the first time the pathway regulating
DC apoptosis in sepsis induced by Gram-negative bacteria.
Materials and Methods
Materials
The following reagents were purchased as indicated: FITC-labeled mouse
mAbs anti-human or mouse CD1a, MHC class I and class II, CD80, CD86,
CD40, CD14, CD3, CD11c, and PE-labeled anti-mouse CD11b from BD
Pharmingen (San Diego, CA); mouse mAbs anti-inducible NO synthase
(anti-iNOS) from BD Transduction Laboratories (Lexington, KY); FITC-
labeled mouse-mAb anti TLR4 (HTA125) from Abcam (Cambridge,
U.K.); FITC-labeled goat-anti-rabbit and Cy7-labeled goat anti-mouse IgG
from Jackson ImmunoResearch Laboratories (West Grove, PA); FITC-la-
beled recombinant human annexin V from Bender MedSystems (Wien,
Austria); recombinant human TNF-, (Z)-1-[2-(2-aminoethyl)-N-(2ammo-
nioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO), and H-(1,2,4)-ox-
adiazolo[4,3-]quinoxalin-1-one (ODQ) from Alexis Italia (Florence, Italy);
diacylglycerol kinase from BIOMOL (Hamburg, Germany); C2 ceramide,
tricyclodecan-9-yl xanthate (D609), and KT5823 from Calbiochem (Bad
Soden, Germany); recombinant human IL-4 from BD Pharmingen recom-
binant human GM-CSF from Schering Plough (Milan, Italy); recombinant
mouse IL-4 and GM-CSF from R&D Systems (Minneapolis, MN); Ficoll-
Paque from BioChrom (Berlin, Germany); magnetic Dynabeads M-450
goat anti-mouse IgG from Dynal Biotech (Oslo, Norway); [-32P]ATP,
[N-methyl-14C]sphingomyelin, and Percoll from Amersham Biosciences
(Little Chalfont, U.K.); the E. coli DH5 strain from BD Clontech (San
Diego, Ca); the Cell Tracker Orange 5-(6)-(((chloromethyl)benzo-
yl)amino) tetramethyl rhodamine (CMTMR) from Molecular Probes
(Eugene, OR); and LPS (from E. coli serotype 055:B5), imipramine, manu-
mycin A, human placental A-SMase, and all other chemicals from Sigma-
Aldrich (St. Louis, MO). Reagents for cell culture were purchased from
Invitrogen Life Technologies (Gaithersburg, MD), except for FCS (clone
III), which was obtained from HyClone-Celbio (Milan, Italy). The goat anti
A-SMase serum (described in Refs. 34 and 35) and scyphostatin were gifts
from Dr. E. Gulbins (University of Essen, Essen, Germany) and Dr. T.
Ogita (Sankyo, Tokyo, Japan), respectively.
Animals
Wild-type (w.t.) female C57BL/6 (H-2b) mice, 6–8 wk of age, were pur-
chased from Charles River Laboratories (Calco, Italy). Female C57BL/6
iNOS/ mice (The Jackson Laboratory, Bar Harbor, ME) were provided
by Dr. S. Cuzzocrea (University of Messina, Messina, Italy). Animals were
housed in the pathogen-free facility at our institution and treated in accor-
dance with the European Community guidelines and the approval of the
institutional ethical committee.
Preparation of immature and mature DCs
Human immature DCs were obtained from PBMC by 5-day culture in the
presence of human GM-CSF (50 ng/ml) and IL-4 (1000 U/ml) exactly as
previously described (36). Depletion of residual T lymphocytes from im-
mature DCs was routinely performed by incubating the cell preparations
with the anti-CD3 mAb (1 g/106 cells) and goat anti-mouse IgG-coated
Dynabeads M-450 as previously described (37). Residual lymphocytes ac-
counted for 1% of the total cells. Mouse immature DCs were obtained
from bone marrow precursors harvested from femurs and tibias of
C57BL/6 mice by a 5-day culture with recombinant murine GM-CSF (20
ng/ml) and IL-4 (5 ng/ml) exactly as previously described (38). Human
mature DCs were obtained from immature DCs by a 48-h incubation in
culture medium in the presence of human TNF- (50 ng/ml). Maturation
was routinely assessed by measuring the exposure on the plasma mem-
brane of specific molecules expressed by immature DCs and known to be
increased in mature DCs, namely MHC class I and class II molecules,
CD80, CD86, and CD40, involved in T cell costimulation. The expression
of these molecules was analyzed by flow cytometry using a FACS
(FACStar Plus; BD Biosciences, Sunnyvale, CA) after staining with ap-
propriate FITC-labeled Abs as previously described (36, 37). Expression of
the macrophage marker CD14 was never observed. The same protocol was
used to measure the surface expression levels of TLR4 in both mature and
immature human DCs. To detect intracellular A-SMase, cells were previ-
ously fixed with paraformaldehyde (4% in PBS for 10 min at room tem-
perature), then permeabilized for 20 min at room temperature in PBS sup-
plemented with 1% BSA and 0.1% saponin. The primary Ab was detected
by flow cytometry using a FITC-labeled goat anti-rabbit secondary Ab. An
isotype-matched Ab was used as a control.
Bacterial culture and preparation
E. coli DH5 cells were cultured to late log phase in Luria broth at 37°C,
centrifuged, heat-inactivated (30 min at 56°C), and resuspended (1011
cells/ml) in culture medium. The bacteria were added to immature and
mature DCs at various E. coli:DC ratios for 48 h. Some of the experiments
were repeated using live bacteria, with results consistent with those ob-
tained with the inactivated bacteria. In these experiments DCs were ex-
posed to E. coli for 1 h at various E. coli:DC ratios; bacteria were then
removed by washing, medium was supplemented with gentamicin (50 g/
ml) and tetracycline (30 g/ml), and DCs were maintained in the culture
medium for an additional 47 h.
Pharmacological treatments
The conditions and concentrations of use of the various compounds inter-
fering with the SMase/ceramide and NO signaling pathways have been
described in detail previously (31, 33, 36, 37, 39). In brief, cell incubations
with D609, manumycin A, scyphostatin, DETA-NO, 8 Br-cGMP, ODQ,
KT5823, C2 ceramide, and exogenous A-SMase were performed for 10
min and those with imipramine for 1 h before LPS or E. coli administra-
tion. In the experiments in which cells were exposed to DETA-NO, the
compound was dissolved in the culture medium 20 min before addition to
the cells. Under these conditions the compound releases constant concen-
trations of NO, as measured using an NO-detecting electrode with a sen-
sitivity of 1 nM (Mark-2 ISO NO, World Precision Instruments, Sarasota,
FL) (40).
All solutions were prepared endotoxin-free. Endotoxin contamination in
all drug solutions was routinely assessed by the Limulus amebocyte geli-
fication test, performed according to the manufacturer’s instructions (PBI,
Milan, Italy). All reagents, including the medium, scored negative.
Apoptosis detection
After pretreatment with the various compounds, DCs were treated at 37°C
for 48 h in the culture medium with various concentrations of LPS or E.
coli. Apoptosis was measured by flow cytometry, using two different pro-
tocols (29). In the first, phosphatidylserine exposure in propidium iodide-
excluding cells was monitored by staining for 15 min at room temperature
with FITC-labeled annexin V (2 g/ml). In the second approach, cells were
ethanol-fixed, permeabilized with 0.01% Nonidet P-40, and stained with 50
g/ml propidium iodide (29). The hypodiploid DNA peak in single-pa-
rameter DNA histograms typical of apoptotic cells was then identified.
Measurement of ceramide concentrations
DCs (106 cells/sample), preincubated at 37°C in 80 l of culture medium
with the various compounds, were exposed to LPS (100 g/ml). At the
time points indicated, incubation was stopped by the addition of 300 l of
ice-cold CH3OH/CHCl3 (2/1, v/v). Samples were then supplemented with
100 l of CHCl3 and 100 l of NaCl (1 M). Ceramide generation was
assessed by the diacylglycerol kinase assay, followed by TLC as described
previously (36).
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Measurement of SMase activities
DCs (2  106 cells/ml) preincubated at 37°C in culture medium with the
various compounds were then treated with LPS (100 g/ml). At the time
points indicated, the incubations were terminated by rapid immersion of
reaction tubes in a methanol/dry ice bath. The suspensions were centri-
fuged, and the cell pellets were washed once with ice-cold PBS. Pellets
were homogenized, supplemented with [N-methyl-14C]sphingomyelin (55
mCi/mmol; 50,000 dpm/assay), and acid and neutral SMase activities were
determined by measuring the conversion of sphingomyelin to phosphoryl-
choline as previously described (41).
In vivo studies
Immature murine w.t. and iNOS/ DCs were cultured in the presence or
the absence of DETA-NO (10 M), 8-bromo-cGMP (8-Br-cGMP; 1 mM),
or imipramine (20 M) for 16 h and labeled with 10 M of the fluorescent
dye CMTMR for 30 min (38). In vitro analysis showed that DC retained the
dye for up to 72 h after loading. The various DC preparations (2.0  106
cells in 100 l) were injected into the spleens of C57BL/6 female w.t. or
iNOS/ mice (groups were of 16 mice for each DC preparation). Thirty
minutes later, 11 animals/group were injected i.p. with a high dose of LPS
(20 mg/kg), and five were given vehicle (control) as previously described
(42). None of the vehicle-injected animals died during the experimental
period. The survival of LPS-treated animals did not vary significantly
among the groups treated with the various DC preparations. Animals were
killed by neck dislocation at various time points as indicated in Results, and
single spleen cell suspensions prepared. Cell numbers obtained from each
spleen were determined and ranged between 98 and 105  106. No sig-
nificant differences were observed in the numbers of cells recovered from
control and LPS-animals. Samples of 1  106 cells from each preparation
were analyzed by flow cytometry, and CMTMR cells were identified as
DCs, because in control experiments they stained positively for the CD11c
DC marker. DC apoptosis was measured by flow cytometry after annexin
V staining. The iNOS expression in total spleen cell suspensions, macro-
phages, and DCs was measured by flow cytometry in permeabilized cells
as described above for A-SMase.
Statistical analysis
The results are expressed as the mean  SEM; n represents the number of
individual experiments. Statistical analysis was performed using Student’s
t test for unpaired variables (two-tailed).
FIGURE 1. LPS and E. coli induce
cell death via apoptosis of immature
human DCs. A–D, Immature human
DCs were exposed for 48 h to E. coli at
various ratios or to increasing concen-
trations of LPS, as indicated in each
panel. Cell samples were then col-
lected and analyzed for various param-
eters describing cell death. A and B,
Cell death, considered the percentage
of cells that stained positively for an-
nexin V, propidium iodide, or both
(n  5). C and D, Apoptosis, assessed
by flow cytometry measuring annexin
V staining in propidium iodide-ex-
cluding cells (n  4). E and F, DNA
content analyzed by flow cytometry
measuring the binding of propidium
iodide in permeabilized cells (x-axis,
arbitrary units). DC treatment with E.
coli (E. coli:DC ratio, 750:1) and LPS
(100 g/ml) results in the formation of a
sub-G1, hypodiploid DNA peak. The
panels show an experiment representa-
tive of four reproducible ones per-
formed. Numbers in the panels indicate
the percentage of cells  SEM, mea-
sured in the fluorescence range indicated
by the bars, in the four experiments..
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Results
E. coli and LPS trigger apoptotic death of immature human
DCs in a concentration-dependent way
Human monocyte-derived immature DCs were treated for 48 h in
the culture medium with increasing amounts of either E. coli or
LPS. Cell death was barely detectable up to a bacteria:DC ratio of
250:1 and an LPS concentration of 1 g/ml. At higher concentra-
tions, however, both stimuli triggered DC death (Fig. 1, A and B),
which was mostly due to apoptosis, because it was accompanied
by phosphatidylserine exposure to the outer leaflet of the DC
plasma membrane (measured by annexin V staining in propidium
iodide-excluding cells; Fig. 1, C and D) and by the appearance of
a hypodiploid DNA peak (Fig. 1, E and F).
LPS activates A-SMase and generates ceramide in immature
human DCs
Because LPS mimicked the effect of E. coli in inducing apoptosis
of DCs, we decided to use the glycolipid to identify the signaling
events involved in this process, concentrating on the ceramide sig-
naling pathway. LPS (100 g/ml) triggered an early wave of cer-
amide generation, which was detectable after 5 min, peaked at 30
min, and decreased thereafter (Fig. 2A). No further increases in
ceramide were detected in the following 4 h (not shown). Cer-
amide can be generated either through the de novo pathway or
after hydrolysis of sphingomyelin by plasma membrane SMases.
These pathways, however, have different patterns of activation
during apoptosis, with activation of SMases occurring as an early
event, and stimulation of the de novo pathway beginning later
(24–26). We therefore concentrated on SMases. As shown in Fig.
2B, LPS triggered a time-dependent activation of A-SMase,
whereas it did not activate the neutral SMase. To assess the role of
A-SMase in LPS-induced ceramide generation, we used a panel of
structurally unrelated inhibitory compounds. To inhibit A-SMase,
we used imipramine, which induces proteolysis of the enzyme (31,
33–35), and D609, which inhibits the phosphatidylcholine-specific
phospholipase C, an enzyme known to be involved in A-SMase
activation by LPS and other stimuli through generation of diacyl-
glycerol (22, 23, 31, 33, 39, 43). As controls of specificity we used
scyphostatin and manumycin A, which are inhibitors of the neutral
SMase (39, 44, 45). When administered alone, none of the com-
pounds had any effect on basal sphingomyelin hydrolysis (not
shown). At the concentrations used, however, imipramine (20 M)
and D609 (25 g/ml) inhibited both A-SMase activity and cer-
amide generation triggered by LPS, whereas scyphostatin (1 M)
and manumycin A (5 M) did not have any effect (Fig. 2, C and
D). These results indicate that activation of A-SMase accounts for
the generation of ceramide triggered by LPS.
FIGURE 2. Exposure of immature human DCs to LPS results in acti-
vation of A-SMase and generation of ceramide. Immature human DCs
were treated with LPS (100 g/ml) for different periods (A and B) or for 30
min (C and D) with or without D609 (25 g/ml), imipramine (Imi; 20 M),
scyphostatin (Scypho; 1 M), or manumycin A (Manu; 5 M) as indicated
in the keys to the various panels. Ceramide levels (A and D) were quan-
tified by TLC. Cer and Or in A indicate the positions of the standard
ceramide loaded in parallel and of the origin. Values reported in D repre-
sent the percent increase over basal ceramide concentration (36  3.10
pmol/mg proteins; n  10). The activities of the neutral SMase (N-SMase)
and A-SMase (B and C) were quantified by measuring generation of phos-
phorylcholine from sphingomyelin. Values are expressed as the percent
increase over basal SMase activity (1.42  0.52 and 0.37  0.23 nmol/
mg/h for A-SMase and N-SMase, respectively; n  5). Asterisks refer to
the statistical significance in LPS-treated cells vs untreated controls;
crosses refer to the statistical significance in cells treated with LPS plus
D609 or LPS plus Imi vs cells treated with LPS alone (n  5; , p 
0.001; , p  0.001). The radiography shown in A is representative of
five reproducible experiments.
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Activation of A-SMase accounts for the E. coli- and
LPS-induced apoptosis of immature human DCs
We used A-SMase inhibitors to evaluate the contribution of this
enzyme to DC apoptosis triggered by E. coli and LPS. When ad-
ministered alone, neither D609 nor imipramine had any apprecia-
ble effect on apoptosis. However, they inhibited apoptosis induc-
tion by both E. coli and LPS (Fig. 3). Of importance, exogenous
C2 ceramide (20 M), although ineffective when administered
alone, reversed the inhibitory effect of D609 and imipramine on
E. coli- and LPS-induced apoptosis. The two neutral SMase in-
hibitors, used as controls, had no effect (not shown). These results
indicate that A-SMase has a key role in the apoptotic signaling
triggered by E. coli and LPS.
NO inhibits the E. coli- and LPS-induced apoptosis of immature
human DC through a cGMP-dependent pathway
To analyze the role of NO, we used DETA-NO, a compound
known to release a constant flux of NO with a period of 20 h.
When DETA-NO was administered at 10, 50, and 100 M, the
steady state concentrations of NO in the medium, measured with
an NO electrode (40), were 0.028  0.001, 0.051  0.002, and
0.12  0.04 M (n  4), respectively. As shown in Fig. 4A,
FIGURE 3. Inhibition of A-SMase protects immature human DCs from
E. coli- and LPS-induced apoptosis. Immature human DCs were exposed
for 48 h to E. coli (E. coli:DC ratio, 750:1), LPS (100 g/ml), D609 (25
g/ml), imipramine (Imi; 20 M), or C2 ceramide (C2; 20 M) in various
combinations as detailed in the keys to the panels. Phosphatidylserine ex-
posure was quantified by annexin V staining as described in Fig. 1. As-
terisks refer to the statistical significance in E. coli- or LPS-treated cells vs
untreated controls; crosses refer to the statistical significance in cells
treated with E. coli plus D609 or E. coli plus Imi vs cells treated with E.
coli alone and in cells treated with LPS plus D609 or LPS plus Imi vs cells
treated with LPS alone (n  4; , p  0.001; , p  0.01).
FIGURE 4. NO inhibits E. coli- and LPS-induced apoptosis of imma-
ture human DCs through a cGMP/G kinase-dependent pathway. Immature
human DCs were exposed for 48 h to E. coli (E. coli:DC ratio, 750:1), LPS
(100 g/ml), 8-Br-cGMP (1 mM), ODQ (1 M), KT5823 (1 M), or
DETA-NO (100 M when the concentration is not specified). Phosphati-
dylserine exposure was quantified by annexin V staining as described in
Fig. 1. Asterisks refer to the statistical probability in E. coli- or LPS-treated
cells vs untreated controls; crosses refer to the statistical significance in
cells treated with E. coli plus DETA-NO or E. coli plus 8-Br-cGMP vs
cells treated with E. coli alone, and in cells treated with LPS plus
DETA-NO or LPS plus 8-Br-cGMP vs cells treated with LPS alone (n 
4; , p  0.001; , p  0.001).
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DETA-NO, although ineffective when administered alone, inhib-
ited both E. coli- and LPS-induced apoptosis in a concentration-
dependent manner.
Among the signaling pathways mediating the biological action
of NO, activation of guanylate cyclase and the ensuing generation
of cGMP appear relevant to human DC functions (36, 37). To
analyze the dependence of the inhibitory effect of NO on cGMP
generation, cells were exposed to E. coli or LPS in the presence of
the membrane-permeant cGMP analog, 8-Br-cGMP (1 mM), or
DETA-NO (100 M) together with either ODQ (1 M), a specific
inhibitor of guanylate cyclase (46), or KT5823, an inhibitor of G
kinase (47). The compounds had no effect when administered
alone; however, 8-Br-cGMP mimicked, whereas ODQ and
KT5823 prevented, the inhibitory effect of DETA-NO on both
LPS- and E. coli-induced apoptosis (Fig. 4, B and C). These results
indicate that NO inhibits apoptosis via a mechanism involving ac-
tivation of guanylate cyclase, formation of cGMP, and activation
of G kinase.
The protective effect of NO is due to the cGMP-dependent
inhibition of A-SMase
Treatment of DCs with DETA-NO inhibited both the activation of
A-SMase and the generation of ceramide triggered by LPS. More-
over, this effect of NO was mimicked by 8-Br-cGMP and was
prevented by ODQ or KT5823 (Fig. 5, A and B). Basal sphingo-
myelin hydrolysis was not modified when DETA-NO, ODQ,
KT5823, or 8-Br-cGMP was administered alone (not shown).
These results indicate that NO inhibits A-SMase activation by LPS
in a cGMP/G kinase-dependent manner.
We then investigated whether the cGMP-dependent inhibition
of A-SMase activity accounts for NO protection from E. coli- and
LPS-induced apoptosis. Administration of either DETA-NO or
8-Br-cGMP inhibited apoptosis to an extent similar to that ob-
served with D609 (Fig. 5, C and D). In addition, when the NO
donor or the cyclic nucleotide was administered together with
D609, apoptosis was inhibited no further. Finally, administration
of C2 ceramide (20 M) reversed the protective effect on apoptosis
of DETA-NO and 8-Br-cGMP, administered alone or in combina-
tion with D609 (Fig. 5, C and D, and not shown). These results
indicate that inhibition of A-SMase activity and of the ensuing
ceramide generation accounts for the cGMP-dependent, inhibitory
effect of NO on LPS- and E. coli-induced apoptosis.
Mature human DCs are resistant to E. coli- and LPS-induced
apoptosis because of their reduced expression of A-SMase
Immature DCs were treated with TNF- (50 ng/ml) for 2 days. The
TNF--induced differentiation of DCs toward a mature, Ag-pre-
senting phenotype includes the coordinated up-regulation of pro-
teins on the plasma membrane, among which are MHC classes I
and II and the CD80, CD86, and CD40 costimulatory molecules
(48). Maturation of DCs was routinely checked by measuring the
expression of these proteins by flow cytometry as described pre-
viously (not shown) (36, 37).
FIGURE 5. The protective effect of NO/cGMP on E. coli- or LPS-in-
duced human DC apoptosis is mediated through inhibition of A-SMase.
Immature human DCs were exposed for 48 h to E. coli (E. coli:DC ratio,
750:1), LPS (100 g/ml), 8-Br-cGMP (1 mM), ODQ (1 M), KT5823 (1
M), DETA-NO (100 M), D609 (25 g/ml), or C2 ceramide (C2; 20
M) as detailed in the keys to the various panels. Ceramide generation (A),
A-SMase activity (B), and phosphatidylserine exposure (C and D) were
measured as described in Figs. 1 and 2. Asterisks in A refer to the statistical
significance (p 0.001) in LPS-treated cells vs untreated controls (n 5);
asterisks in C and D (p  0.001) refer to the statistical significance in cells
treated with E. coli, D609, C2, and DETA-NO (or 8-Br-cGMP), and with
LPS, D609, C2, and DETA-NO (or 8-Br-cGMP) vs cells treated in the
same way but in the absence of C2 (n  5). Crosses in B refer to the
statistical significance (p  0.001) in cells treated with LPS plus
DETA-NO or LPS plus 8-Br-cGMP vs cells treated with LPS alone. The
radiography shown in A is representative of four reproducible experiments.
Cer and Or indicate the positions of the standard ceramide loaded in par-
allel and the origin.
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At variance with immature DCs, exposure of mature DCs to
LPS resulted in neither generation of ceramide (Fig. 6A) nor ac-
tivation of SMases (not shown). In addition, mature DCs did not
undergo apoptosis when exposed to either E. coli or LPS. Sensi-
tivity to apoptosis, however, was restored by administration, to-
gether with LPS or E. coli, of exogenous C2 ceramide or A-SMase
(2.0 U/ml; Fig. 6B). We then investigated the molecular basis of
the difference in sensitivity to LPS and E. coli between mature and
immature DCs. In particular, we measured the expression levels of
both A-SMase and the LPS TLR4 (49). In agreement with previous
results (50) we did not find any difference in the levels of the TLR4
(Fig. 6C). By contrast, the levels of A-SMase were significantly
lower in mature DC with respect to those observed in immature
FIGURE 6. Resistance of mature human DCs to E. coli- and LPS-in-
duced apoptosis is due to reduced A-SMase expression and impaired cer-
amide generation. Human immature DCs (iDCs) were treated with TNF-
(50 ng/ml) for 2 days. A, TNF--treated, mature DCs (mDCs) were ex-
posed to LPS (100 g/ml), and ceramide content was measured by TLC at
the indicated time points. Cer and Or indicate the positions of the standard
ceramide loaded in parallel and the origin. B, mDCs were treated for 30
min with E. coli (E. coli:DC ratio, 750:1), LPS (100 g/ml), C2 ceramide
(C2; 20 M), or human placental A-SMase (2.0 U/ml) in various combi-
nations as detailed in the key. Phosphatidylserine exposure was quantified
by annexin V staining as described in Fig. 1. Asterisks refer to the statis-
tical significance (p  0.001) in cells treated with E. coli plus C2 or E. coli
plus A-SMase vs cells treated with E. coli alone, and in cells treated with
LPS plus C2 or LPS plus A-SMase vs cells treated with LPS alone (n 4).
C, Comparison of the expression levels of the TLR4 and A-SMase in iDCs
vs mDCs. Cell preparations were decorated with FITC-stained Abs specific
for the two Ags, as detailed on the left, and were analyzed by flow cytom-
etry (). Their relative fluorescence intensity (RFI) was calculated vs neg-
ative controls (f). The results shown are from one experiment represen-
tative of four reproducible ones. The RFI reported in the panels are the
mean  SEM in the four experiments. Asterisks refer to the statistical
significance (p  0.001) in mDCs vs iDCs.
FIGURE 7. Apoptosis of immature murine DCs depends on A-SMase
activation and is inhibited by NO through cGMP/G kinase-dependent in-
hibition of A-SMase activity. Immature murine DCs were treated for 30
min (A) or 48 h (B) with LPS (100 g/ml), DETA-NO (100 M), 8-Br-
cGMP (1 mM), ODQ (1 M), KT5823 (1 M), imipramine (Imi; 20 M),
or C2 ceramide (C2; 20 M) in various combinations as detailed in the
keys to the panels. A-SMase activity (A) and phosphatidylserine exposure
(B) were measured as described in Figs. 1 and 2. Asterisks in A refer to the
statistical significance in LPS-treated cells vs untreated controls; asterisks
in B refer to the statistical significance (p  0.001) in cells treated with
LPS, DETA-NO, and ODQ (or KT5823) vs cells treated with LPS plus
DETA-NO. Crosses in A refer to the statistical significance (p  0.001) in
cells treated with LPS plus DETA-NO or LPS plus 8-Br-cGMP vs cells
treated with LPS alone; crosses in B refer to the statistical significance (p
0.001) in cells treated with LPS, DETA-NO, and C2; LPS, 8-Br-cGMP,
and C2; or LPS, Imi, and C2 vs cells treated in the same way but in the
absence of C2 (n  4).
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DCs. Taken together, these results indicate that down-regulation of
A-SMase is responsible for the insensitivity of mature DCs to
LPS/E. coli-induced apoptosis.
Activation of A-SMase and its inhibition by NO/cGMP regulate
sensitivity to LPS-induced apoptosis in immature murine DCs
Immature murine DCs were obtained from mouse bone marrow
progenitors as previously described (38). We first characterized the
LPS-induced SMase activities and apoptosis as well as the effects
of NO/cGMP on these parameters. Exposure of DCs to LPS (100
g/ml) for 30 min did not activate neutral SMase (not shown), but
gave rise to a significant activation of A-SMase (1.13  0.03 and
2.07  0.11 nmol/mg/h before and after LPS administration, re-
spectively; p  0.01; n  4), which was inhibited by 91  5.2%
(n  4) in the presence of imipramine. A-SMase activation was
also inhibited when DCs were exposed to LPS in the presence of
FIGURE 8. Treatment of immature DCs with NO, cGMP, or the A-SMase inhibitor imipramine confers resistance to LPS-induced apoptosis in an in
vivo model of sepsis. A, Diagrammatic representation of the experimental protocol. Immature DCs obtained from w.t. and iNOS/ mice were treated for
16 h in the absence (UT-DCs) or the presence of DETA-NO (100 M; DETA-NO-DCs), 8-Br-cGMP (1 mM; 8 Br-cGMP-DCs), or imipramine (Imi; 20
M; Imi-DCs), stained with the red fluorescent dye CMTMR (10 M), and injected into the spleens of w.t. or iNOS/ C57BL/6 mice (2.0  106
cells/animal; 0.5 h). Thirty minutes later (time zero), mice were injected i.p. with either LPS (20 mg/kg) or vehicle. Spleens were removed after 4, 12,
24, 36, 48, and 72 h, and spleen suspensions were prepared. B--D, Comparison of iNOS expression in spleen suspensions from vehicle-injected and
LPS-injected w.t. mice at the 12 h point, measured by flow cytometry as described in Fig. 6. Shown are the levels of expression measured in the total cell
suspension (B), in CD11b/CD11c macrophages (C), and in CMTMR DCs (D). The relative fluorescence intensity (RFI; ) was calculated vs negative
controls (f). The results shown are from one experiment representative of three reproducible ones. The RFI reported in the panels are the mean  SEM
in the three experiments. Asterisks refer to the statistical significance (, p 0.01; , p 0.001) in iNOS expression of LPS-injected vs vehicle-injected
mice (n  3). E–G, Phosphatidylserine exposure by CMTMR DCs was measured after annexin V staining of the various cell preparations as described
in Fig. 1. E, W.t. DCs injected into w.t. mice; F, w.t. DCs injected into iNOS/ mice; G, iNOS/ DCs injected into w.t. mice. f, F, Œ, and , UT-DCs,
DETA-NO-DCs, 8-Br-cGMP-DCs, and Imi-DCs, respectively. Filled and open symbols refer to DCs retrieved from LPS-injected and vehicle-injected mice,
respectively. Asterisks refer to the statistical significance in DETA-NO-DCs vs UT-DCs (, p  0.01; , p  0.001); crosses to the statistical
significance in w.t. UT-DCs, vs iNOS/ UT-DCs (, p  0.05; , p  0.01; , p  0.001), analyzed after injection in w.t. mice treated with LPS
(n  3).
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DETA-NO. The effect of the NO donor was mimicked by 8-Br-
cGMP and was prevented by either ODQ or KT5823 (Fig. 7A).
LPS also triggered DC apoptosis that was inhibited to similar ex-
tents by imipramine, 8 Br-cGMP, and DETA-NO, the latter in an
ODQ- and KT5823-sensistive fashion (Fig. 7B). Furthermore, sen-
sitivity to apoptosis was in all cases restored by administration of
C2 ceramide (Fig. 7B). Neither apoptosis nor changes in sphingo-
myelin hydrolysis were observed when DETA-NO, ODQ,
KT5823, 8-Br-cGMP, imipramine, or C2 ceramide was adminis-
tered alone (not shown). Taken together these results indicate that
LPS triggers apoptosis of murine DCs in an A-SMase-dependent
way, and that protection by NO occurs through inhibition of the
activity of the enzyme in a cGMP-dependent way. Thus, murine
immature DCs behave similarly to their human counterparts.
Generation of NO by iNOS and inhibition of A-SMase protect
immature murine DCs from LPS-induced apoptosis in an in vivo
model of sepsis
A model of sepsis was used to investigate in vivo the relevance of
A-SMase activation and its inhibition by NO/cGMP in murine DC
apoptosis. Because iNOS plays fundamental roles in the regulation
of immune responses, and its expression may be triggered by LPS
(32), we evaluated the role of endogenous NO generated by this
enzyme. Fig. 8A shows a diagram of the protocol used in these
experiments. DCs, derived from w.t. or iNOS/ mice, were
treated ex vivo for 16 h in the absence or the presence of DETA-
NO, 8-Br-cGMP, or imipramine, stained with the fluorescent dye
CMTMR, which is retained by the cells for long periods, and then
injected into the spleen of w.t. or iNOS/ C57BL/6 mice. Thirty
minutes later, mice were injected i.p. with either LPS (20 mg/kg)
or vehicle, and spleens were removed 4, 12, 36, 48, and 72 h
thereafter. Two types of studies were conducted using this proto-
col. We first measured iNOS expressed by spleens cells derived
from w.t. mice injected with untreated w.t. DCs. Although cells
from vehicle-injected mice did not express iNOS, those recovered
from LPS-injected mice expressed the enzyme from the 12 h point
throughout the 72-h observation period (Fig. 8B and not shown).
Most iNOS-expressing cells were CD11b/CD11c macrophages
(Fig. 8C). In contrast, DCs did not express the enzyme at any time
point (Fig. 8D).
We then analyzed apoptosis of the injected, CMTMR DCs.
The numbers of CMTMR DCs in spleen cell suspensions in each
experimental condition are specified in Table I. Fig. 8, E and F,
reports the results obtained using w.t. DCs, untreated or treated ex
vivo with DETA-NO or 8-Br-cGMP before their injection into
spleen. Treatment of the mice with LPS induced apoptosis of un-
treated DCs. Apoptosis increased with the time of exposure to LPS
in vivo and was significantly higher in DCs recovered from
iNOS/ mice than in DCs recovered from w.t. mice, indicating
that generation of endogenous NO played a protective role (com-
pare E and F in Fig. 8). This was confirmed by the observation that
DCs treated ex vivo with DETA-NO or 8-Br-cGMP before their
injection into LPS-treated w.t. and iNOS/ mice were signifi-
cantly protected from apoptosis (Fig. 8, E and F). Of importance,
protection from apoptosis under these conditions was similar to
that observed in DCs treated with imipramine (Fig. 8, E and F).
Finally, we analyzed apoptosis of iNOS/ DCs treated ex vivo in
the presence or the absence of DETA-NO, 8-Br-cGMP, or imip-
ramine and then injected into w.t. animals. Sensitivity to LPS-
induced apoptosis in these cells was similar to that found in their
w.t. counterparts (compare E and G in Fig. 8), providing a func-
tional correlate to the observation, reported in Fig. 8D, that DCs do
not express iNOS in LPS-treated mice in vivo. In control experi-
ments using vehicle-treated mice, DC apoptosis was always neg-
ligible (Fig. 8, E–G).
Table I. Numbers (106) of CMTFR DCs recovered from vehicle- and LPS-treated mice
Mouse DCs
Mouse
Treatment DC Treatment
Time (h) of Recovery
4 12 24 36 48 72
w.t. w.t. Vehicle UT 1.99  0.025 1.65  0.017 1.37  0.032 1.28  0.026 1.20  0.035 0.98  0.046
DETA-NO 1.99 0.008 1.61  0.020 1.36  0.019 1.29  0.030 1.20  0.023 0.97  0.033
8-Br-cGMP 1.99 0.015 1.63  0.009 1.37  0.027 1.28  0.039 1.18  0.028 0.98  0.040
Imipramine 1.98 0.017 1.60  0.018 1.38  0.023 1.28  0.019 1.21  0.036 0.96  0.037
LPS UT 1.95  0.035 1.59  0.020 1.28  0.022 1.10  0.030 0.95  0.028 0.80  0.045
DETA-NO 1.94 0.012 1.57  0.032 1.26  0.033 1.08  0.027 0.95  0.033 0.80  0.042
8-Br-cGMP 1.95 0.015 1.59  0.037 1.26  0.030 1.05  0.019 0.94  0.039 0.79  0.051
Imipramine 1.96 0.023 1.58  0.028 1.27  0.029 1.08  0.034 0.95  0.027 0.80  0.049
iNOS/ w.t. Vehicle UT 1.99  0.025 1.65  0.017 1.37  0.032 1.28  0.026 1.20  0.035 0.97  0.052
DETA-NO 1.98 0.008 1.61  0.020 1.36  0.019 1.29  0.030 1.21  0.040 0.96  0.050
8-Br-cGMP 1.98 0.015 1.63  0.009 1.37  0.027 1.28  0.039 1.18  0.028 0.96  0.038
Imipramine 1.99 0.017 1.60  0.018 1.38  0.023 1.28  0.019 1.21  0.036 0.96  0.047
LPS UT 1.94  0.042 1.58  0.031 1.27  0.037 1.09  0.017 0.95  0.019 0.79  0.035
DETA-NO 1.93 0.033 1.57  0.027 1.25  0.042 1.09  0.039 0.95  0.009 0.78  0.038
8-Br-c-GMP 1.93 0.025 1.57  0.040 1.26  0.015 1.07  0.024 0.95  0.024 0.78  0.042
Imipramine 1.93 0.030 1.56  0.023 1.26  0.035 1.08  0.014 0.96  0.036 0.79  0.030
w.t. iNOS/ Vehicle UT 1.99  0.040 1.67  0.022 1.40  0.032 1.30  0.009 1.25  0.035 0.98  0.029
DETA-NO 1.98 0.020 1.65  0.027 1.39  0.021 1.29  0.025 1.21  0.021 0.98  0.034
8-Br-c-GMP 1.98 0.025 1.65  0.031 1.37  0.030 1.30  0.040 1.21  0.042 0.98  0.037
Imipramine 1.98 0.032 1.67  0.037 1.38  0.018 1.30  0.027 1.23  0.006 0.97  0.054
LPS UT 1.93  0.037 1.57  0.020 1.26  0.034 1.12  0.050 0.95  0.054 0.79  0.024
DETA-NO 1.92 0.044 1.56  0.032 1.26  0.047 1.10  0.031 0.94  0.049 0.80  0.036
8-Br-c-GMP 1.93 0.049 1.56  0.037 1.25  0.051 1.09  0.029 0.93  0.047 0.79  0.051
Imipramine 1.93 0.037 1.56  0.028 1.27  0.037 1.10  0.043 0.93  0.041 0.79  0.032
Immature murine w.t. and iNOS/ DCs were cultured in the absence (UT) or presence of DETA-NO (10 M), 8 Br-cGMP (1 mM), or imipramine (20 M) for 16 h and
labeled with 10 M of the fluorescent dye CMTMR for 30 min (38). The various DC preparations (2.0  106 cells in 100 l) were injected into the spleens of C57BL/6 female
w.t. or iNOS/ mice. LPS or vehicle was injected i.p. 30 min later (42). Animals were killed at the indicated time points, spleens were recovered, and CMTMR CD11c DCs
were identified by flow cytometry. The number of CMTMR DCs was determined in 1  106 cell samples from each spleen preparation and normalized to the total number
of cells (both CMTMR and CMTMR) recovered from the same spleen (n  3).
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Taken together our results demonstrate that activation of
A-SMase in DCs and their exposure to NO generated by iNOS-
competent cells play crucial roles during LPS-induced DC apo-
ptosis in vivo and strongly suggest that protection by NO/cGMP in
vivo occurs through inhibition of A-SMase activation.
Discussion
In this study we examined, by both an in vitro approach and an in
vivo model of sepsis, the relevance of A-SMase and its regulation
by NO in the E. coli/LPS-induced apoptosis of DCs. Using human
and murine DCs, we show that the in vitro interaction with E. coli
can trigger apoptotic cell death of immature DCs and that a single
pathogen-associated molecular pattern, LPS, is sufficient to acti-
vate the process. We found that the mechanism of death induction
by LPS requires activation of the sphingomyelin-hydrolyzing en-
zyme, A-SMase, and generation of ceramide. The obligatory role
of this pathway is demonstrated by two observations. Firstly, phar-
macological inhibition of A-SMase prevents ceramide generation
and apoptosis induction by LPS. Secondly, reduced expression of
A-SMase, with no detectable ceramide generation, occurs in ma-
ture DCs, which are resistant to LPS-induced apoptosis; sensitivity
to apoptosis could be restored in these cells by administration of
exogenous ceramide or A-SMase. The in vivo relevance of this
observation was validated using a model of LPS-induced sepsis. In
this model we found that DCs injected in septic mice were com-
mitted to die unless they were previously exposed to the A-SMase
inhibitor imipramine.
The role of A-SMase in apoptosis has been established for var-
ious cell types, especially after the development of a knockout
mouse model for the enzyme (51). Resistance to apoptosis induced
by various stimuli was observed, among others, in lymphocytes,
hepatocytes, macrophages, and endothelial cells from A-SMase
knockout mice (27, 52–56), confirming and expanding the data
obtained through pharmacological inhibition of the enzyme (29,
30, 57–59). All these cells participate in sepsis together with DCs
(60) and undergo apoptotic death (6–8, 61–63). The involvement
of A-SMase in apoptosis, however, appears to depend on the stim-
ulus and the cell type involved (53, 64). With the notable exception
of endothelial cells (27) in no other cell type has it been established
whether the sepsis-induced apoptosis is mediated through the same
A-SMase-dependent pathway we found activated in DCs. Eluci-
dation, in the A-SMase/ mouse model, of which other cells are
protected from apoptosis would be important to define precisely
the biological role of A-SMase in sepsis.
Although obligatory, A-SMase activation might not be the only
signaling event involved in DC apoptosis induced by LPS. The
biological effects of this glycolipid are known to be mediated by
synergic cooperation of various signaling pathways, including the
transcription factor NF-B, G proteins, and several protein kinases
belonging to the Akt, JNK, mitogen-activated, stress-activated,
and Src-related families (15–18, 20, 21, 23, 65, 66), some of which
activated as a consequence of A-SMase stimulation (22, 23, 65).
Whether and how activation of one or more of the above signaling
pathways contributes to apoptosis induced by high concentrations
of LPS remain to be investigated.
The second important finding of our study is that NO protects
DCs from apoptosis in sepsis and that the mechanism of its action
is the inhibition of A-SMase. The importance to DC protection of
NO generated by iNOS during sepsis was clearly demonstrated in
the in vivo model by two lines of evidence. First, DCs died from
apoptosis faster and at higher rates in iNOS/ mice than in w.t.
mice; second, exposure to exogenous NO/cGMP or imipramine
increased DC survival significantly.
We did not find significant differences in resistance to apoptosis
between w.t. and iNOS/ DCs. A likely explanation comes from
the observation that in vivo, LPS did not trigger iNOS expression
in w.t. DCs. Similarly to iNOS/ DCs, therefore, w.t. DCs were
exposed only to the NO generated by neighboring, iNOS-compe-
tent cells. Interestingly, human DCs do not express iNOS when
exposed to cytokines and bacterial products (36, 37). Our in
vivo results, therefore, may also be a valid model for human DC
during sepsis. At variance with the situation in vivo, some in
vitro studies showed that murine DCs express iNOS after stim-
ulation with LPS and cytokines (32), confirming the reported
variability in the expression of the enzyme among in vivo and
in vitro models (67, 68).
The observation that NO protects DCs against apoptosis is rel-
evant to the overall understanding of the role of this messenger in
sepsis. NO is known to induce both detrimental effects, such as
hypotension, vasoplegia, lactic acidosis, and impaired thermoreg-
ulation, and beneficial actions, such as maintenance of renal and
hepatosplancnic blood flow, inhibition of platelet aggregation, and
maintenance of the cardiac function (68–70). The survival to sep-
sis of iNOS/ mice was found to be less than, more than, or equal
to that of their w.t. counterparts depending on the model of endo-
toxemia, thus reflecting the complexity of the actions of NO de-
scribed above (71–75). Despite this complexity, however, iNOS-
generated NO has been shown to contribute substantially to
protection from apoptosis during sepsis in various organs, includ-
ing liver, heart, kidney, and thymus (74, 76–79). To date, the in-
tracellular signal transduction events responsible for such protec-
tive action had been studied to only a limited extent. Our in vitro
results show that inhibition of A-SMase is central to the protective
action of NO in DCs, and that this inhibition occurs through stim-
ulation of guanylate cyclase, generation of cGMP, and activation
of protein kinase G. These findings provide a target and a mech-
anism of action for NO that may open new vistas to our under-
standing of apoptosis in sepsis and its prevention.
In particular, relevant to apoptosis in sepsis are activation of
caspases, changes in the expression levels of members of the Bcl-2
family of proteins, and reduction in the mitochondrial membrane
potential (63). In various models of apoptosis, all these signaling
events have been reported to be inhibited by NO, acting through
cGMP (80). Likewise, inhibition of these events also takes place as
a consequence of inhibition of A-SMase, including that by NO
(24–26, 29–31, 33, 57). It is conceivable, therefore, that the inhi-
bition of A-SMase by NO shown in this study switches off the
signaling pathways leading to sepsis-induced apoptosis, thus act-
ing as a key mechanism of protection.
Protection of immune-competent cells, including DCs, from ap-
optosis has been recently envisaged as a means to ameliorate the
multiple organ failure/dysfunction syndrome and thus the final
outcome of the disease (63). The obligatory role of A-SMase in
E. coli/LPS-induced apoptosis of DCs and its regulation by NO/
cGMP revealed by our studies may therefore be relevant to the
development of sepsis. The experimental protocol we used for our
in vivo experiments was designed to specifically study the mech-
anism of protection of DCs from sepsis induced-apoptosis and not
the possible beneficial role of this protection as a therapeutic strat-
egy. However, our results suggest that DCs obtained from
A-SMase/ mice (51) may have a potential role in sepsis, ame-
liorating the immune suppression associated with this condition.
Validation of the protective effect of A-SMase/ DCs by appro-
priate models (48) may be the first step in developing new thera-
peutic approaches to this disease.
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